Muted Sanofi hits new 52-week low, shares face cautious analyst targets
22.06.2026 - 15:25:48 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 15:24.
Sanofi (FR0000127771) touched a new 52-week low on Euronext Paris today, with the shares trading down to 71.50 euros according to market data from the Financial Times. The move comes as the French pharma group announces a new global head of R&D and highlights fresh regulatory approvals in Japan.
What today’s news shows
Sanofi said it appointed Paulo Fontoura as Executive Vice President and Global Head of R&D, effective immediately, in a press release dated June 22, 2026, replacing the previous leadership after a period of drug setbacks in key late-stage programs, as summarized by RTTNews. StockAnalysis overview citing the RTTNews update The company also recently reported that Japan’s Ministry of Health, Labour and Welfare approved the subcutaneous formulation of its multiple myeloma drug Sarclisa in combination therapy, expanding use in a major Asian market. Marketscreener news feed on Sanofi approvals
On Euronext Paris the Sanofi shares traded around 72.79 euros earlier in the session, about 1.8 percent lower on the day, with intraday market data showing the new 52-week low at 71.50 euros and the 52-week high at 91.15 euros in October 2025. FT equity summary for Sanofi in Paris The stock remains a heavyweight in European healthcare indices and trades as American Depositary Receipts on NASDAQ under the ticker SNY.
Analyst estimates and targets
Analyst data compiled by StockAnalysis show Sanofi with trailing twelve-month revenue of about 54.6 billion dollars and net income of 8.71 billion dollars, implying a price-earnings ratio near 11.7 and a forward P/E around 8.6 at the current NASDAQ quotation. StockAnalysis valuation and consensus data The site cites an average analyst rating of “Buy” with a consensus price target of roughly 55.90 dollars for the ADR, about 32 percent above the last close around 42.50 dollars.
On the European side, Deutsche Bank Research recently set a target of 95 euros and reiterated a Buy stance for the Paris-listed shares, according to a Marketscreener summary dated June 15, 2026. Marketscreener compilation of analyst targets for Sanofi Other brokers cited by the same source show a broadly positive stance on the stock, with most recommendations in the Buy or Outperform camp and average targets well above the current 72 to 74 euro trading range.
All news and analysis on the Sanofi shares
From Paris trading data to analyst targets and regulatory updates, the Sanofi coverage hub on ad-hoc-news.de aggregates current reports and background for active investors.
The therapies behind the stock
Sanofi generates most of its revenue from prescription medicines in areas such as immunology, oncology, rare diseases and vaccines, with flagship products including the asthma and atopic dermatitis treatment Dupixent and the multiple myeloma antibody Sarclisa. The company also maintains a significant vaccines franchise through Sanofi Pasteur, covering influenza, pediatric and travel vaccines worldwide.
Where the Sanofi shares trade today
The Sanofi shares (FR0000127771) trade on 2026-06-22, 15:00, on Euronext Paris at 72.79 euros.
Key data on the Sanofi shares
- Company: Sanofi S.A.
- ISIN: FR0000127771
- WKN: 920657
- Ticker: SAN
- Trading venue: Euronext Paris
- Price (as of 2026-06-22, 15:00): 72.79 EUR
- Market cap: 91.5 billion EUR (as of 2026-06-22)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: CAC 40, STOXX Europe 600 Health Care
- Next earnings date: 2026-07-30
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Historical data and analyst estimates are no guarantee of future performance. Investors should conduct their own research or consult a qualified advisor.
